Open access

Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Alrik Gustafson S. Nance B. Gryder Nama Shendy L. Wick G. McKay-Corkum K. Ritter S. Purdy Arthur Wolin Sheera R. Rosenbaum S. Mathavarajah NA Demelfi Y. Wang Y. Zhang Mark W. Zimmerman AM Kavariyani EA Citarella VJ Ebegboni J. Hardin A. Laveck X. Wang NV Dharia AL. Hong G. Kugener JS Boehm J. Roth J. Khan F. Vazquez Kristin B. Artinger R. Zhao Dm M. Langenau J. Qi K. Stegmaier Brian J. Abraham HL Ford A. Durbin

Sep 2026 · bioRxiv · 0 citations

Biology Medicine

TL;DR

A novel approach to target RMS transcription comprising simultaneous targeting of two distinctly acting transcriptional co-activators dually targets CRC-associated co-activators to cooperatively suppress the RMS transcriptome and enforce cell death.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Sep 2026

Abstract B005: Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Rhabdomyosarcoma (RMS) is a high-risk pediatric sarcoma that resembles developing skeletal muscle. Transcriptional dysregulation drives RMS pathogenesis in tumors carrying chimeric transcription factors (“fusion-positive (FP)”), and those without (“fusion-negative” (FN)). Here, we develop a novel approach against RMS...

Brian J. Abraham, Annika L. Gustafson, S. Nance et al. · Cancer Research · 0 citations

Sep 2026

Abstract B011: Oncogenic neomorphic ATRX-in-frame fusion mutations mechanistically enforce a new immunotherapeutic vulnerability through altered epigenomic regulation

It is identified that ATRX-IFF neuroblastomas display a unique epigenomic and transcriptomic landscape, with newly established gene enhancers at sites of ATRX-IFF binding in regions of open chromatin that result in transcriptional upregulation of target genes.

M. A. Mohammad Nezhady, S. Sati, D. E. Prado et al. · Cancer Research · 0 citations

Conference Open access 2026

Role of EZH2 in Regulating EGR1 in Rhabdomyosarcoma

Background: EGR1, one of the immediate-early response genes, plays an important role as a mediator for transmitting extracellular stimuli. EGR1 is down regulated in many cancers. Many studies show that it functions as a tumor suppressor gene in a variety of cancers. EGR1 also acts as an oncogene in number of cancers...

Trefa S. Mohamad · BIO Web of Conferences · 0 citations

Sep 2026

Abstract PR007: Overcoming drug resistance in Sonic hedgehog-driven medulloblastoma

Medulloblastoma (MB) is the most common malignant brain tumor in children, and the Group 2 (Sonic Hedgehog; SHH) subtype is driven by aberrant activation of the SHH signaling pathway. Several FDA-approved therapies target oncogenic SHH signaling by inhibiting SMOOTHENED (SMO), the primary membrane-associated regulato...

Rodney A. Stewart, Mattie Casey, Annabel Lee et al. · Cancer Research · 0 citations

Open access Oct 2026

Co-targeting ASAH1 and the histone reader BRD1 potently suppresses TNBC growth through the transcriptional repressor BCL6

Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited targeted therapeutic options, leading to higher mortality rates compared to other breast cancer subtypes. In our previous study, we identified that N-acyl sphingosine amidohydrolase 1 (ASAH1) is overexpressed in TNBC cells, a...

S. C. Chabattula, Patrick T. Ball, Alok Kartha et al. · Oncogenesis · 0 citations

Open access Sep 2026

EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer.

Phenotypic plasticity is a recognized mechanism of therapeutic resistance in prostate cancer (PCa); however, current knowledge of its underlying drivers and therapeutic interventions remain limited. Using genetically engineered mouse models (GEMMs) devoid of Pten and Rb1, we previously demonstrated the chromatin reprog...

Beatriz German, K. Morel, Teia Noel et al. · Cell Reports Medicine · 0 citations